Hepatitis C News and Research

Latest Hepatitis C News and Research

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

24 Mar 2014

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia.

19 Mar 2014

Viewpoints: The lesson from Florida's special election; hospital deaths; costs of treating hep C

But in recent months, the political landscape has grown bleaker [for Democrats] .... The question, of course, is why so many Republicans turned out [in the Florida special election last week] and why so few Democrats did. The answer among strategists on both sides was: Obamacare. But not in the sense that the healthcare law is so unpopular that Democrats are doomed; in fact, as more people sign up for health coverage, polls suggest that Obamacare is a little less toxic now than it was last fall. Instead, the problem is that a high-decibel debate over Obamacare has the effect of prompting conservatives to come out and vote, but not liberals (Doyle McManus, 3/16).

18 Mar 2014

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV.

18 Mar 2014

Viewpoints: The impact of Florida's special election; drug testing for doctors; the toll from Alzheimer's

A rule of electoral politics is that when a Democratic wave is building, the media broadcast it like a foregone conclusion. When a Republican wave is building, Beltway pundits are the last to admit it. After Tuesday's GOP win in a Florida special House election, even the press corps now agrees that Republicans are poised for major gains in November, assuming the GOP has the wit to exploit it (3/12).

14 Mar 2014

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

More than 100 million humans around the world are infected with hepatitis C virus. The infection gives rise to chronic liver inflammation, which may result in reduced liver function, liver cirrhosis and liver cancer.

14 Mar 2014

Hepatitis C drug fuels cost debate

A panel of experts said this week that the drug represents a "low value" to the health system because of its cost.

13 Mar 2014

First Edition: March 12, 2014

Today's headlines include stories about the Obama administration's latest tallies regarding how many Americans have signed up for Obamacare coverage and the outcome of a Florida special election that was marked by health law themes.

12 Mar 2014

Parasites in human are most likely to interact via food source

Over 1,400 species of parasites - viruses, bacteria, fungi, intestinal worms and protozoa - are able to infect humans. In most cases, the right medicine against a parasite cures the patient.

12 Mar 2014

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Now that the badly botched rollout of the federal government's health care website seems to be behind us, Republicans have shifted their criticisms to several states that are experiencing problems enrolling people on their state-run exchanges.

12 Mar 2014

Experimental drugs offer hope for people with hepatitis C

Patrizia Cazzaniga had heard the horror stories about early treatments for hepatitis C - multiple daily pills and weekly shots for up to a year, side effects that could be debilitating, and a cure rate of only about 40 percent.

11 Mar 2014

First Edition: March 10, 2014

Today's headlines include reports about how the Virginia Assembly's impasse on Medicaid expansion is playing out.

10 Mar 2014

Longer looks: Health care in jail; preventing Medicare drug fraud; new medical codes

"Sheriff Ashe," [the waitress] began. "My daughter is in your jail." She then told me her daughter's story. "Laura," as I'll call her here, was a bright and sociable girl who, after graduating from high school, went on to community college.

10 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

A new study from the University of Washington has found that performance on Lumosity games can distinguish between patients with cirrhosis of the liver, pre-cirrhotic patients, and healthy controls. The study used Lumosity games as psychometric tests to detect subtle cognitive impairments in patients with cirrhosis. The study is published in the March issue of the American Journal of Gastroenterology.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Viewpoints: The lesson from Florida's special election; hospital deaths; costs of treating hep C

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

Viewpoints: The impact of Florida's special election; drug testing for doctors; the toll from Alzheimer's

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

Hepatitis C drug fuels cost debate

First Edition: March 12, 2014

Parasites in human are most likely to interact via food source

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Experimental drugs offer hope for people with hepatitis C

First Edition: March 10, 2014

Longer looks: Health care in jail; preventing Medicare drug fraud; new medical codes

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Mastering RNA extraction for plant and fungal research – eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in